Jane Street Group LLC purchased a new stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 35,299 shares of the biotechnology company’s stock, valued at approximately $130,000.
A number of other institutional investors have also added to or reduced their stakes in the business. Two Sigma Investments LP purchased a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at about $146,000. Goldman Sachs Group Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 297.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 173,078 shares of the biotechnology company’s stock valued at $637,000 after purchasing an additional 129,488 shares during the period. Quantitative Investment Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at about $203,000. BlueCrest Capital Management Ltd acquired a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at about $275,000. Finally, Allianz Asset Management GmbH increased its holdings in shares of Arrowhead Pharmaceuticals by 2.2% in the fourth quarter. Allianz Asset Management GmbH now owns 462,105 shares of the biotechnology company’s stock valued at $1,701,000 after purchasing an additional 9,985 shares during the period. Institutional investors own 26.88% of the company’s stock.
A number of research analysts have recently weighed in on the company. BidaskClub lowered Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday. Jefferies Group assumed coverage on Arrowhead Pharmaceuticals in a report on Tuesday, March 27th. They issued a “buy” rating and a $10.00 price objective on the stock. ValuEngine raised Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Chardan Capital reissued a “neutral” rating on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 16th. Finally, B. Riley increased their price objective on Arrowhead Pharmaceuticals from $3.00 to $4.00 and gave the company a “neutral” rating in a report on Monday, February 12th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Arrowhead Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $6.30.
In related news, CFO Kenneth Allen Myszkowski sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, March 27th. The stock was sold at an average price of $8.00, for a total transaction of $160,000.00. Following the sale, the chief financial officer now directly owns 330,815 shares of the company’s stock, valued at $2,646,520. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Christopher Richard Anzalone sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $7.43, for a total value of $743,000.00. Following the sale, the chief executive officer now directly owns 2,194,789 shares in the company, valued at $16,307,282.27. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 440,000 shares of company stock worth $3,266,600. 4.60% of the stock is owned by corporate insiders.
Shares of ARWR stock opened at $6.97 on Monday. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $604.91, a PE ratio of -14.83 and a beta of 2.36. Arrowhead Pharmaceuticals has a fifty-two week low of $1.42 and a fifty-two week high of $8.09.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Friday, February 9th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.04). The firm had revenue of $3.51 million during the quarter, compared to analyst estimates of $8.71 million. Arrowhead Pharmaceuticals had a negative net margin of 116.17% and a negative return on equity of 42.52%. research analysts anticipate that Arrowhead Pharmaceuticals will post -0.71 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/23/35299-shares-in-arrowhead-pharmaceuticals-arwr-purchased-by-jane-street-group-llc.html.
Arrowhead Pharmaceuticals Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals (NASDAQ:ARWR).
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.